NCT06208345 Early Life Intervention in Pediatrics Supported by E-health
| NCT ID | NCT06208345 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Adiposity |
| Study Type | INTERVENTIONAL |
| Enrollment | 148 participants |
| Start Date | 2024-02-16 |
| Primary Completion | 2028-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 148 participants in total. It began in 2024-02-16 with a primary completion date of 2028-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Contact & Investigator
Matthias V. Kopp, Prof. Dr.
PRINCIPAL INVESTIGATOR
Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
Frequently Asked Questions
Who can join the NCT06208345 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Adiposity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06208345 currently recruiting?
Yes, NCT06208345 is actively recruiting participants. Contact the research team at matthias.kopp@insel.ch for enrollment information.
Where is the NCT06208345 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT06208345 clinical trial?
NCT06208345 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Matthias V. Kopp, Prof. Dr. at Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland. The trial plans to enroll 148 participants.